Replimune, Inc.

← The SEC Ephemeris: the whole map

Replimune, Inc. vusolimogene oderparepvec

In the graph: all 12 documents (182 pages).

Ticker: REPL
Product: vusolimogene oderparepvec
Disease area: Not yet classified
Response path: Not yet classified
Complete Response Letters: April 10, 2026 · July 21, 2025

From FDA letters and SEC filings. Not investment or medical advice.

Not yet classified

Otsuka Pharmaceutical Company, Ltd. ABILIFY MAINTENA
OWP Pharmaceuticals, Inc. this action
Par Sterile Products, LLC Micafungin
Pfizer Inc. Trazimera
Pfizer Ireland Pharmaceuticals MOD-4023
AB Pharmaceuticals, LLC the following drug product: > Efavirenz
PharmaEssentia Corporation P1101
Pharmaxis Ltd. Bronchitol
Phathom Pharmaceuticals, Inc. Voquezna
Pierre Fabre Pharmaceuticals Inc. tabelecleucel®
Polarean Inc. Xenoview
Provention Bio, Inc. PRV-031
Proximagen, LLC Nayzilam
PTC Therapeutics, Inc. vatiquinone
RB Health (US) LLC naproxen sodium |)
Recordati Rare Diseases Inc. Cystadrops
Recro Pharma Inc. Meloxicam
RedHill Biopharma Ltd. Rizaport
Regeneron Pharmaceuticals, Inc. BLA
REGENXBIO, Inc. clemidsogene lanparvovee
Replimune, Inc. vusolimogene oderparepvec
ResQ Pharma
Revance Therapeutics, Inc. daxibotulinumtoxinA
Ricon Pharma, LLC Cyclophosphamide
Rocket Pharmaceuticals, Inc. marnetegragene autotemcel manufactured
Rosemont Pharmaceuticals Holdings, Inc. valacyclovir
Roxane Laboratories, Inc. Cyclophosphamide
Salamandra, LLC rosuvastatin
Samsung Bioepis Co., Ltd. Pyzchiva
Sandoz Inc. EG12014
sanofi-aventis U.S. LLC Fexinidazole
Santen, Inc. Omlonti
Saol International Development Limited sodium dichloroacetate
Sarepta Therapeutics, Inc. Vyondys
Sarfez Pharmaceuticals Inc. pd Pe or to section
Scholar Rock, Inc.
Scienture Inc. losartan potassium
Scilex Pharmaceuticals, Inc. ZTlido
scPharmaceuticals, Inc. Furoscix™ Furosemide)
scPharmaceuticals Services, Inc Furoscix™ “

All 283 on the full map →

Group by

Build queue · replay at pipeline speed